about
Disruption of Myosin 1e promotes podocyte injuryThe extracellular matrix in development and morphogenesis: a dynamic view.A mouse Col4a4 mutation causing Alport glomerulosclerosis with abnormal collagen α3α4α5(IV) trimers.X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndromeThe effect of progressive glomerular disease on megalin-mediated endocytosis in the kidneyAortic abnormalities in males with Alport syndrome.Mild electrical stimulation and heat shock ameliorates progressive proteinuria and renal inflammation in mouse model of Alport syndromeSearching for a treatment for Alport syndrome using mouse modelsRapid identification of a disease allele in mouse through whole genome sequencing and bulk segregation analysis.Women and Alport syndrome.Minor Type IV Collagen α5 Chain Promotes Cancer Progression through Discoidin Domain Receptor-1.Type IV procollagen missense mutations associated with defects of the eye, vascular stability, the brain, kidney function and embryonic or postnatal viability in the mouse, Mus musculus: an extension of the Col4a1 allelic series and the identificatiProgression of Alport Kidney Disease in Col4a3 Knock Out Mice Is Independent of Sex or Macrophage Depletion by Clodronate TreatmentUnderstanding hereditary diseases using the dog and human as companion model systems.X-Linked Alport Dogs Demonstrate Mesangial Filopodial Invasion of the Capillary Tuft as an Early Event in Glomerular Damage.Glomerular pathology in Alport syndrome: a molecular perspective.Podocyte p53 Limits the Severity of Experimental Alport Syndrome.Hematopoietic stem cells are pluripotent and not just "hematopoietic".Crack Propagation Versus Fiber Alignment in Collagen Gels: Experiments and Multiscale Simulation.Quaternary epitopes of α345(IV) collagen initiate Alport post-transplant anti-GBM nephritisLigand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.A synaptic nidogen: developmental regulation and role of nidogen-2 at the neuromuscular junctionCell Receptor-Basement Membrane Interactions in Health and Disease: A Kidney-Centric ViewCOL4A6 is dispensable for autosomal recessive Alport syndrome.Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease.Stem cell therapy for Alport syndrome: the hope beyond the hype.The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis?Integrins in renal development.Stem cells as a therapeutic approach to chronic kidney diseases.Evidence for activation of the unfolded protein response in collagen IV nephropathiesA potential target gene for the host-directed therapy of mycobacterial infection in murine macrophages.Identification of noncollagenous sites encoding specific interactions and quaternary assembly of alpha 3 alpha 4 alpha 5(IV) collagen: implications for Alport gene therapy.Bromide supplementation exacerbated the renal dysfunction, injury and fibrosis in a mouse model of Alport syndrome.Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease.Pathogenicity of a Human Laminin β2 Mutation Revealed in Models of Alport Syndrome.STAT3 inhibition attenuates the progressive phenotypes of Alport syndrome mouse model.End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases.Long-term treatment with EGFR inhibitor erlotinib attenuates renal inflammatory cytokines but not nephropathy in Alport syndrome mouse model.The triple helix of collagens - an ancient protein structure that enabled animal multicellularity and tissue evolution.
P2860
Q28509726-B307C0E9-E18D-4B95-9CFC-22849CBE0AE6Q30432483-DEB83B43-FA22-48A4-BDDB-616A168BD55BQ33692564-994C8D2E-251A-48CE-A176-C2ACA4EF78BEQ33988983-1501C709-6210-4C3F-8CDB-4A397059F41DQ34021381-A7556CCC-221D-4712-B6B6-37B6EBA4B118Q34308226-31CD2B61-8CEC-4013-89A5-9E457C663517Q34399470-D508A5F2-BF11-4666-A65C-FE5D61C48948Q34453272-94F826E0-7666-40CD-8FFD-FA5E98B40C6BQ34714895-84CC56B0-3A14-4D14-BE91-629148F5FB2DQ35571750-DEE05721-B97F-4F72-B5B3-C9A817B301D1Q35635931-EF892200-A9EC-4E32-B4AD-CF1EF18BF9A5Q35641621-DB913625-8E51-48F8-B8BB-E5115F21A99DQ35837373-2E3C21FB-A37E-4AB2-9F87-F8EF7BDCFCBCQ36021334-0CD2322B-DD94-4E44-A01C-0D5853AC8919Q36222337-13F564AB-81D3-4F62-BBC5-EA4D9CF2D6B9Q36359599-A0804C0B-F4D2-481B-96B8-ACACCA9FC26BQ36417903-3D4D34F1-951E-464E-9493-BAB812B534D5Q36824005-E63E7DDC-03A3-4533-BDA1-BACA577530E4Q36833101-91624626-488E-428D-880C-808324B08991Q36880447-A679DE90-324B-42F7-A758-D094185BE822Q36905955-A7D14C50-28CC-4B2D-9735-E3932A88F080Q36936640-EDF6D15E-1CE5-41D8-9177-D64C4DF213E9Q37019135-4E2E7AEA-DCC7-4E27-BF00-003043D558C0Q37063978-FEAE5993-84DD-4E2E-BCF5-56A6E14A9B13Q37427367-AF24F3BC-1947-4A53-92E2-8609D2DDF4F8Q37463203-4C0E7F38-7DD6-4867-98FD-2E1CC0107798Q37702664-2F3F2FC0-BD81-4115-8460-4F86B7392744Q37878382-BCF48DD3-B526-429E-914A-AC33B963825EQ37962831-4FAF5F53-8BC4-4AA3-ACA3-E1FBFB01E99DQ38311017-C1039E6F-BF5B-4DDD-B082-5E92D6907A14Q38757143-EE839B46-A179-44CC-8C0D-90D8EEE2E91CQ41176703-35CBF5F1-0CD4-47A3-8FE7-2CF6448C0E1CQ41618166-A734F30B-ADEA-457A-A90B-EE738DE23F14Q42054644-8956227E-803D-485B-91C7-E9A73314D672Q47273807-97EA654A-D04A-4D40-B498-FE742877E342Q47587148-1A43D27B-5FE8-417A-BDDD-556EEE66B8C0Q51125064-07C2E65C-2B25-493C-8822-67A2D1420C57Q51147438-076F1E94-39BF-4DD5-8F77-5A1267BEB9ABQ52720562-27A1976A-6328-4AF9-B8B9-79393D1EF897
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Mouse model of X-linked Alport syndrome.
@en
Mouse model of X-linked Alport syndrome.
@nl
type
label
Mouse model of X-linked Alport syndrome.
@en
Mouse model of X-linked Alport syndrome.
@nl
prefLabel
Mouse model of X-linked Alport syndrome.
@en
Mouse model of X-linked Alport syndrome.
@nl
P2093
P50
P1476
Mouse model of X-linked Alport syndrome
@en
P2093
Clifford E Kashtan
John T Crosson
Stefan M Kren
William Thomas
Yoav Segal
Yoshikazu Sado
P304
P356
10.1097/01.ASN.0000130562.90255.8F
P577
2004-06-01T00:00:00Z